Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:GWPH

GW Pharmaceuticals (GWPH) Stock Price, News & Analysis

GW Pharmaceuticals logo

About GW Pharmaceuticals Stock (NASDAQ:GWPH)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$218.96
$218.96
50-Day Range
$216.90
$219.28
52-Week Range
$87.07
$219.57
Volume
N/A
Average Volume
899,771 shs
Market Capitalization
$6.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Remove Ads
Receive GWPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GW Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

GWPH Stock News Headlines

The Dirty Secret About Gold Mining Stocks...
Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.
GWPRF Historical Data
George Washington University
GW Pharmaceuticals PLC (GWPRF)
See More Headlines

GWPH Stock Analysis - Frequently Asked Questions

GW Pharmaceuticals plc (NASDAQ:GWPH) announced its quarterly earnings data on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.63) by $0.27. The business's revenue for the quarter was up 50.7% on a year-over-year basis.

Based on aggregate information from My MarketBeat watchlists, some other companies that GW Pharmaceuticals investors own include NVIDIA (NVDA), Canopy Growth (CGC), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

Last Earnings
11/03/2020
Today
4/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GWPH
Fax
N/A
Employees
1,161
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,020,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$311.33 million
Cash Flow
$0.01 per share
Price / Cash Flow
18,588.22
Book Value
$23.48 per share
Price / Book
9.33

Miscellaneous

Free Float
N/A
Market Cap
$6.86 billion
Optionable
Optionable
Beta
2.15

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:GWPH) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners